Capstan Therapeutics to Participate in Upcoming Industry Conferences

2023-09-26

siRNA

SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the following upcoming industry conferences: Jefferies Cell and Genetic Medicine Summit Date: Tuesday, September 26, 2023 Time: 12:45 p.m. EDT Location: New York, NY Chief Scientific Officer and Executive Vice President of R&D, Adrian Bot, M.D., Ph.D., will participate in a virtual panel discussion titled “CAR T Beyond Cancer.” 2023 Cell & Gene Meeting on the Mesa Date: Tuesday, October 10, 2023 Time: 9:30 a.m. PT Location: Rentschler ATMP Ballroom at the Park Hyatt Aviara Resort in Carlsbad, CA Chief Scientific Officer and Executive Vice President of R&D, Adrian Bot, M.D., Ph.D., will give a company presentation. BMO Biopharma Spotlight Series: (R)Evolution of RNA Therapies Date: Tuesday, October 10, 2023 Location: Virtual Company management will participate in 1:1 investor meetings. Leerink Partners Biopharma Private Company Connect Date: Wednesday, October 25 – Thursday, October 26, 2023 Location: Virtual Company management will participate in 1:1 investor meetings. About Capstan ( ) Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. For more information, please visit and follow us on LinkedIn.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构